The Ginseng and Eleuthero Adulteration Problem: What an Analytical Testing Laboratory Finds That a Standard COA Misses

Of all the botanicals we’ve tested over the years, ginseng consistently produces the most uncomfortable conversations. Not because the chemistry is complicated — though it is — but because the gap between what a supplier’s certificate of analysis claims and what an analytical testing laboratory actually finds is, in this category, genuinely alarming.

Published market analyses of commercial ginseng products in the US have documented adulteration or mislabeling rates ranging from 30–45% depending on the distribution channel and the rigor of testing applied. Some failures are subtle: wrong species, low potency, diluted with inert filler. Others are more brazen. What they share is that none of them would have been caught by a supplier COA review and a visual inspection — the bare-minimum approach more common than it should be.

Why Ginseng and Eleuthero Draw Adulterators

The economic incentive here is unusually strong, even by botanical industry standards. Standardized Panax ginseng root extract standardized to ≥6% ginsenosides can trade at $80–150/kg from reputable Korean or Chinese suppliers. Siberian ginseng — properly called Eleutherococcus senticosus, or eleuthero — costs $8–18/kg in bulk. That’s a 5–10× price differential for botanicals that share a common name in casual usage and are virtually indistinguishable as dried, milled powders.

And here’s what makes this substitution so persistent: eleuthero is not an invented, fraudulent material. It’s a legitimate botanical with its own USP monograph and a real market. But it is not Panax ginseng. It contains eleutherosides — not ginsenosides. Its pharmacological profile is different. The clinical research supporting it is different. When a brand’s label reads “Panax ginseng” and the incoming raw material barrel contains Eleutherococcus senticosus, that is a misbranded dietary supplement under 21 CFR Part 101 and potentially adulterated under 21 CFR Part 111. That’s not a technicality — it’s a federal violation.

What makes it harder to catch than you’d expect: the substitution can survive basic HPLC testing if the supplier has spiked the extract with isolated ginsenoside reference standards. We’ve seen COAs from overseas brokers listing Rg1 and Rb1 percentages that looked perfectly compliant on paper. The identity underneath was wrong.

The Adulterants an Analytical Testing Laboratory Actually Encounters

Eleuthero-for-Panax is the most common full substitution, but the botanical adulterant landscape is more varied than that. These are the patterns that show up regularly when samples come through our facility:

Species substitution within Panax itself. Panax notoginseng (sanqi ginseng or tienchi) is often cheaper than P. ginseng or P. quinquefolius (American ginseng) and shares several ginsenoside markers. At low HPLC resolution, a partial substitution blends in. HPTLC fingerprinting reveals the difference clearly — the chromatographic pattern is distinct between species at UV 366 nm with anisaldehyde staining — but only if the testing laboratory actually runs it.

Codonopsis pilosula (dang shen) as a dilutant. Codonopsis is a legitimate TCM ingredient sometimes informally called “false ginseng.” It contains no ginsenosides whatsoever. In powdered form, it is nearly impossible to distinguish visually or by organoleptic testing. It’s used as a bulking adulterant in quantities ranging from 10–40% by weight, with the ginsenoside content in the remaining fraction inflated enough to hit a minimum potency threshold.

Starch and maltodextrin cut. Less sophisticated, but encountered with some frequency in lower-cost imports. FTIR scanning flags it quickly. HPLC ginsenoside content drops proportionally to the dilution fraction, so the failure usually shows up in potency testing if the method is properly validated and not just accepting “within ±10% of label claim.”

Phytolacca americana (American pokeweed) root fragments. This one warrants particular concern. Pokeweed root contains phytolaccine and pokeweed antiviral protein — toxic glycoproteins associated with gastroenteritis and more serious adverse effects. FDA has issued import alerts for Chinese herbal products where Phytolacca adulterants were detected in ginseng-labeled material. This is documented in peer-reviewed literature and FDA action records, not speculation.

How a Credible Testing Program Approaches Ginseng Raw Materials

A COA from your supplier is a starting point, not a finish line — and for a botanical with this adulteration history, it’s not even close to enough. A defensible program under 21 CFR Part 111 should include four distinct analytical layers:

Step 1: Botanical identity by HPTLC. The USP has published validated TLC and HPTLC identity methods for both Ginseng (Panax ginseng) and American Ginseng (Panax quinquefolius). The ginsenoside fingerprint pattern — the relative positions and intensities of Rb1, Rc, Rd, Re, and Rg1 bands — is species-specific and visually interpretable against a USP reference standard plate. Eleuthero, Panax notoginseng, and Codonopsis each produce patterns that differ materially from genuine Panax ginseng or P. quinquefolius. No other single test gives you that fingerprint-level specificity as quickly.

Step 2: DNA barcoding for orthogonal species confirmation. HPTLC is excellent for fingerprinting, but botanical powders can be analytically challenging when the matrix is complex or the adulterant is a processed extract rather than mechanically ground root. DNA barcoding using the ITS2 and psbA-trnH markers reliably distinguishes Panax quinquefolius from P. ginseng and from Eleutherococcus senticosus, even in finished extracts where physical morphology has been destroyed. Running HPTLC and DNA barcoding together gives you orthogonal confirmation — two independent methods, two independent lines of evidence. If they disagree, you investigate before you accept the lot.

Step 3: Ginsenoside quantification by HPLC. The USP monograph for Ginseng specifies a minimum of 0.40% combined ginsenosides (Rg1 + Re + Rf + Rb1 + Rc + Rb2 + Rd) on a dry-weight basis. For standardized extracts marketed at 5% or 6% ginsenosides, you need HPLC with a validated method and reference standards for at least the six principal ginsenosides. This catches potency failures even when identity technically passes — including situations where a diluted but genuine material slips through identity testing.

Step 4: Elemental impurities by ICP-MS. Cadmium accumulation in Panax ginseng root is a documented and measurable concern, particularly in material cultivated in certain provinces of northeastern China and some Korean-origin material depending on regional soil conditions. ICH Q3D oral supplement limits set cadmium at ≤0.5 µg/g (500 µg per 1 kg body weight per day). We’ve seen incoming ginseng batches test between 0.3–0.9 µg/g total cadmium — which means some lots fail before you’ve even gotten to identity. Lead and arsenic screening under USP <232>/<233> should be part of the same ICP-MS run. They cost essentially nothing incremental once the instrument is set up.

What 21 CFR Part 111 Actually Requires — And Where Brands Fall Short

FDA’s dietary supplement GMP regulations at 21 CFR Part 111 require manufacturers to establish written specifications for each incoming dietary ingredient and component, and to verify that those specifications are met before the material enters production. The regulations don’t prescribe specific methods, which gives brands some flexibility — but it also means “my supplier provided a COA” is not a defensible substitute for actually testing.

In a Form 483 or warning letter context, FDA investigators routinely ask for identity test data — the actual instrument output or laboratory results, not the spec sheet or the supplier’s document. If your SOP states “identity testing per HPTLC” and your batch records show a physical description and organoleptic evaluation, that discrepancy will generate an observation. We’ve worked with brands in the Chicago area and across the Midwest that received exactly this feedback during routine FDA inspections — typically from investigators stationed out of the district office covering Illinois and surrounding states.

The practical requirement: your SOPs should specify the identity method (HPTLC, DNA barcoding, or both), reference materials and acceptance criteria (USP monograph-compliant fingerprint; ≥X% ginsenosides by validated HPLC method), and testing frequency by lot. For ginseng, every-lot testing is the defensible position. The adulteration rate in this category simply doesn’t support skip-lot protocols unless you have multi-year approval history with a supplier under an audited quality agreement.

Building a Program That Holds Up

The supplement brands that manage ginseng incoming testing most effectively run a tiered protocol. New suppliers get the full panel on first three lots: HPTLC identity, DNA barcoding, HPLC ginsenoside quantification, and ICP-MS for Cd, Pb, As, and Hg. Suppliers with three or more passing lots on file move to a streamlined program — HPTLC plus HPLC on every shipment — with the full panel rerun annually or any time the supplier’s cultivation region, extraction source, or quality system changes.

It’s not the cheapest per-lot number. But consider the counterfactual: one FDA warning letter, one retail chain pull, or one serious adverse event tied to a misidentified botanical ingredient carries costs that make three years of incoming testing look like rounding error. Ginseng is not a category where supplier COA review plus organoleptic inspection is a reasonable GMP interpretation. The published adulteration data — and the enforcement record that follows from it — doesn’t support that level of comfort.

If your current incoming testing program for ginseng raw materials ends at the COA, you have a compliance gap. An analytical testing laboratory capable of running HPTLC, DNA barcoding, HPLC, and ICP-MS under accredited conditions can close it — and give you the documented evidence you need if FDA ever asks.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025 Accredited Botanical Identity and Adulteration Testing — Qalitex Laboratories performs HPTLC, DNA barcoding, HPLC, and ICP-MS under ISO 17025 accreditation for supplement brands across North America.